https://www.selleckchem.com/products/AZD0530.html
Copyright ©2020, American Association for Cancer Research.PD-L1 (programmed cell death 1 ligand 1) is a key driver of tumor-mediated immune suppression and targeting it with antibodies can induce therapeutic responses. Given the costs and associated toxicity of PD-L1 blockade, alternative therapeutic strategies are needed. Using reverse-phase protein arrays to assess drugs in use or likely to enter trials, we performed a candidate drug screen for inhibitors of PD-L1 expression and identified verteporfin as a possible small molecule inhi
Like
Comment
Share
